What is the 13F Pro Quality Score for ELDN?

13F Pro ranks Eledon Pharmaceuticals, Inc. (ELDN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELDN's current score at https://13fpro.ai/research/ELDN (free sign-up required for the full ranking).

Which hedge funds own the most ELDN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ELDN include BVF /IL, BlackRock,, Defilade Capital Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ELDN as soon as new 13F filings post.

Where does 13F Pro source ELDN data?

All Eledon Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Eledon Pharmaceuticals, Inc. files with the SEC under CIK 1404281. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELDN in?

Eledon Pharmaceuticals, Inc. (ELDN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELDN research updated on 13F Pro?

ELDN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Eledon Pharmaceuticals, Inc.(ELDN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1404281 ELDN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ELDN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Eledon Pharmaceuticals, Inc. (ELDN), a Healthcare sector company. ELDN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Eledon Pharmaceuticals, Inc. reports net income of $-39.0M, free cash flow of $-22.6M. Top institutional holders of ELDN by reported 13-F value include BVF /IL, BlackRock,, Defilade Capital Management, L.P., based on the most recent SEC filings. ELDN trades on the Nasdaq exchange and files with the SEC under CIK 1404281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eledon Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-39.0M

Free Cash Flow

Q1 2026

$-22.6M

ROIC

Q1 2026

-47.3%

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-32.2% YoY

$-45.6MFY 2025

FY19 $-16.0MFY20 $-22.8MFY21 $-34.5MFY25 $-45.6M

Operating Income

—FY 2025

FY19 $-16.1MFY20 $-18.5MFY21 $-36.9MFY25 —

EPS (Diluted)

+77.7% YoY

$-0.52FY 2025

FY19 —FY20 —FY21 $-2.33FY25 $-0.52

Total Assets

-0.9% YoY

$169.0MFY 2025

FY19 $10.9MFY20 $197.2MFY21 $170.5MFY25 $169.0M

Total Debt

$0.00FY 2025

FY19 $0.00FY20 $0.00FY21 $0.00FY25 $0.00

Op. Cash Flow

-115.6% YoY

$-62.3MFY 2025

FY19 $-13.9MFY20 $-15.2MFY21 $-28.9MFY25 $-62.3M

Metric	FY 2025	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Net Income	$-45.6M -32.2%	$-34.5M -51.3%	$-22.8M -42.5%	$-16.0M -13.8%	$-14.1M -7.2%	$-13.1M
Operating Income	—	$-36.9M -99.7%	$-18.5M -15.0%	$-16.1M -14.2%	$-14.1M -7.2%	$-13.1M
EPS (Diluted)	$-0.52 +77.7%	$-2.33	—	—	—	—
Total Assets	$169.0M -0.9%	$170.5M -13.5%	$197.2M +1703.9%	$10.9M -35.8%	$17.0M -18.5%	$20.9M
Total Debt	$0.00	$0.00	$0.00	$0.00	—	—
Operating Cash Flow	$-62.3M -115.6%	$-28.9M -90.1%	$-15.2M -9.8%	$-13.9M -16.5%	$-11.9M +20.4%	$-14.9M

AI Insight: ELDN Financial Trends

Eledon burns cash consistently with no revenue, equity deteriorating despite zero debt.

• Operating cash flow negative every quarter, ranging from $-8M to $-23M; Q1 2026 worst at $-23M.

• Net income volatile but predominantly negative; Q3 2024 showed $77M gain, isolated exception in otherwise loss-making profile.

• Equity fluctuated $-64M to $81M across 8 quarters; recent Q1 2026 at $45M, down from Q4 2025 peak of $81M.

⚠ No revenue reported across all periods; company is pre-commercialization or non-revenue generating.

⚠ Operating cash burn accelerated to $-23M in Q1 2026; unsustainable without financing or inflection.

⚠ Equity eroded $36M from Q4 2025 to Q1 2026 despite zero debt; runway dependent on capital raises.

AI Insight: ELDN Ratio Trends

Eledon remains unprofitable with deeply negative returns; insufficient operational data to assess margin or cash-generation trends.

• ROE deteriorated sharply to -197.5% in Q3 2025, then recovered to -51.5% in Q4 2025; TTM ROE stands at -174.6%.

• ROA similarly volatile: -53.8% in Q3 2025, improving to -24.7% in Q4 2025; TTM ROA at -53.3%.

• Debt-to-equity ratio remains zero across all periods, indicating no financial leverage.

⚠ Absence of operating margin and net profit margin data prevents assessment of cost control or profitability trajectory.

⚠ Quarterly volatility in ROE and ROA suggests inconsistent or minimal net income; path to breakeven unclear.

Get alerted when ELDN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Eledon Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELDN

BVF INC/IL
$19.4M6,293,282 sh
BlackRock, Inc.
$13.5M4,382,245 sh
Defilade Capital Management, L.P.
$11.0M3,564,127 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.1M3,293,134 sh
Ensign Peak Advisors, Inc
$7.6M2,464,919 sh
Zimmer Partners, LP
$5.8M1,875,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.5M1,791,783 sh
SPHERA FUNDS MANAGEMENT LTD.
$5.5M1,772,131 sh
Catalio Capital Management, LP
$5.1M1,639,816 sh
Blue Owl Capital Holdings LP
$4.4M1,419,912 sh

Fund	Value	Shares
BVF INC/IL	$19.4M	6,293,282
BlackRock, Inc.	$13.5M	4,382,245
Defilade Capital Management, L.P.	$11.0M	3,564,127
VANGUARD CAPITAL MANAGEMENT LLC	$10.1M	3,293,134
Ensign Peak Advisors, Inc	$7.6M	2,464,919
Zimmer Partners, LP	$5.8M	1,875,000
GEODE CAPITAL MANAGEMENT, LLC	$5.5M	1,791,783
SPHERA FUNDS MANAGEMENT LTD.	$5.5M	1,772,131
Catalio Capital Management, LP	$5.1M	1,639,816
Blue Owl Capital Holdings LP	$4.4M	1,419,912

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELDN on your watchlist

Track score changes the day Eledon Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELDN a good stock to buy?

13F Pro's AI-powered analysis of Eledon Pharmaceuticals, Inc. (ELDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELDN are available on the ELDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ELDN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eledon Pharmaceuticals, Inc.'s investment landscape.